Related Experiment Videos
Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia
J J Vredenburgh1, O R McIntyre, G G Cornwell
1Department of Medicine, Dartmouth-Hitchhock Medical Center, Hanover, NH.
Medical and Pediatric Oncology
|January 1, 1988
Summary
Mitoxantrone showed effectiveness in treating relapsed or refractory acute nonlymphocytic leukemia (ANLL), with 47% of patients achieving complete remission. This three-day schedule demonstrated acceptable toxicity and potential for combination therapy in future ANLL studies.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Relapsed or refractory acute nonlymphocytic leukemia (ANLL) presents a significant therapeutic challenge.
- Limited effective treatment options exist for patients with relapsed or refractory ANLL.
Purpose of the Study:
- To evaluate the efficacy and toxicity of a specific mitoxantrone regimen in patients with relapsed or refractory ANLL.
- To determine the response rates and safety profile of a three-day mitoxantrone infusion schedule.
Main Methods:
- Seventeen patients with relapsed or refractory ANLL received mitoxantrone at 14 mg/m2 daily for three days.
- A second course was administered for two days if bone marrow showed residual leukemia on day fourteen.
- Toxicity was monitored, including myelosuppression, hepatic function, and stomatitis.
Main Results:
- Eight patients (47%) achieved complete remission (CR).
- Three patients (17%) had a partial response (PR).
- Seven of 12 relapsed patients and one of five refractory patients achieved CR. Toxicity was acceptable, with manageable myelosuppression, hepatic toxicity, and stomatitis.
Conclusions:
- The three-day mitoxantrone schedule demonstrates significant activity in relapsed and refractory ANLL.
- This regimen is associated with acceptable toxicity, suggesting its potential for combination therapy in future ANLL treatment strategies.